AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...
The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.
Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...
AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with ...
The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.
Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) ...